Search for the Higgs Boson in the Channel H->ZZ*->4l with the ATLAS Detector

The decay channel H->ZZ*->4l provides a clean signature for the Higgs boson in the mass range between ~120 GeV and 2MZ, above which the "gold-plated" channel with two real Z bosons in the final state opens up. The signal cross section is several orders of magnitude smaller than those for the backgrounds, therefore a thorough understanding of the multi-lepton processes is needed to obtain a high background rejection. Crucial for this channel is also a very good knowledge of the trigger and detector response for lepton identification and reconstruction. The observability of the signal on top of the reducible tt, Zbb and of the irreducible ZZz backgrounds with the ATLAS Detector is discussed in the following, with particular emphasis on lepton reconstruction. The ATLAS discovery potential for the H->4l, including the most realistic and up-to-date description of the detector performance, is presented

Search for the Higgs Boson in the Channel H→ZZ(*)→4l with the ATLAS Detector

The decay channel H→ZZ(∗)→4ℓ provides a clean signature for the Higgs boson in the mass range between ∼120 GeV/c2 and 2MZ, above which the gold-plated channel with two real Z bosons in the final state opens up. The signal cross section is several orders of magnitude smaller than those for the backgrounds, therefore a thorough understanding of the multi-lepton processes is needed to obtain a high background rejection. Crucial for this channel is a very good understanding of the trigger and detector response for lepton identification and reconstruction. In order to compute an exclusion limit, a good knowledge of the back- grounds as well as of the signal selection efficiency after all analysis cut is needed. The observability of the signal on top of the reducible t¯t, Zb¯b and W Z and of the irreducible Z Z backgrounds is discussed in detail, with particular emphasis on the lepton reconstruction. We evaluate the ATLAS discovery potential for the H → 4ℓ channel, including the most realistic and up-to-date description of the detector performance

Geant4 Muon Digitization in the ATHENA Framework

The aim of this note is to describe the Muon Digitization software packages, completely re-written to run in the Athena framework and to interface with the Geant4 Muon Spectrometer simulation. The Muon Digitization is the simulation of the Raw Data Objects (RDO), or the electronic output, of the Muon Spectrometer. It consists of two steps: in the first step, the output of the detector simulation, the Muon Hits, is converted to Muon Digits, namely intermediate objects that can be fed into the reconstruction. In the second step, the Muon Digits are converted into RDO, the transient representation of raw data byte stream. We describe the detailed implementation of the first step of the Muon Digitization, where the detector simulation output is âﾜdigitizedâ into Muon Digits. We describe the fundamentals of the Muon Digitization algorithms, outlining their global structure and the infrastructure for the simulation of piled-up events. We also describe the details of the digitization validation procedures against the Monte Carlo information

Implementation of chamber misalignments and deformations in the ATLAS muon spectrometer simulation

"The implementation of run-time dependent corrections for alignment and distortions in the detector description of the ATLAS Muon Spectrometer is discussed, along with the strategies for studying such effects in dedicated simulations."http://deepblue.lib.umich.edu/bitstream/2027.42/64214/1/jpconf8_119_032010.pd

Proceedings of the Workshop on Monte Carlo's, Physics and Simulations at the LHC PART II

These proceedings collect the presentations given at the first three meetings of the INFN "Workshop on Monte Carlo's, Physics and Simulations at the LHC", held at the Frascati National Laboratories in 2006. The first part of these proceedings contains pedagogical introductions to several basic topics of both theoretical and experimental high pT LHC physics. The second part collects more specialised presentations.Comment: 157 pages, 136 figures; contribution by M. Grazzini has been adde

Predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy

n/

Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients

n/

Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy

Aim: Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy. Patients & methods: We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective observational multicenter INVIDIa-2 study in the single center of Parma. Results: Among 53 patients, eight experienced influenza-like illness during the influenza season 2019/2020, and three of them had diagnosis of COVID-19. They were males, elderly, with cardiovascular disease. Radiological features of COVID-19 pneumonitis were found in all of three cases, although the pharyngeal swab resulted positive in only two. Two of these three patients died due to respiratory failure. Conclusion: Cancer patients are at high risk of severe events from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

The Effects of Granulocyte Colony-Stimulating Factor in Patients with a Large Anterior Wall Acute Myocardial Infarction to Prevent Left Ventricular Remodeling. A 10-Year Follow-Up of the RIGENERA Study

Background: the RIGENERA trial assessed the efficacy of granulocyte-colony stimulating factor (G-CSF) in the improvement of clinical outcomes in patients with severe acute myocardial infarction. However, there is no evidence available regarding the long-term safety and efficacy of this treatment. Methods: in order to evaluate the long-term effects on the incidence of major adverse events, on the symptom burden, on the quality of life and the mean life expectancy and on the left ventricular (LV) function, we performed a clinical and echocardiographic evaluation together with an assessment using the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the Seattle Heart Failure Model (SHFM) at 10-years follow-up, in the patients cohorts enrolled in the RIGENERA trial. Results: thirty-two patients were eligible for the prospective clinical and echocardiography analyses. A significant reduction in adverse LV remodeling was observed in G-CSF group compared to controls, 9% vs. 48% (p = 0.030). The New York Heart Association (NYHA) functional class was lower in G-CSF group vs. controls (p = 0.040), with lower burden of symptoms and higher quality of life (p = 0.049). The mean life expectancy was significantly higher in G-CSF group compared to controls (15 +/- 4 years vs. 12 +/- 4 years, p = 0.046. No difference was found in the incidence of major adverse events. Conclusions: this longest available follow-up on G-CSF treatment in patients with severe acute myocardial infarction (AMI) showed that this treatment was safe and associated with a reduction of adverse LV remodeling and higher quality of life, in comparison with standard-of-care treatment